A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants

NCT07218770

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Regeneron Pharmaceuticals
Enrollment	72 participants

Key Eligibility Criteria

Inclusion (4)

- Diagnosis of non-infectious anterior, intermediate, posterior or panuveitis (For anterior uveitis, there must be evidence of inflammation affecting the posterior segment), as defined in the protocol
- Active disease at baseline, as defined in the protocol
- Part A only: Best Corrected Visual Acuity (BCVA) of d65 and \>10 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (Snellen equivalent of worse than or equal to 20/50 and better than 20/630) at the screening visit and on day 1
- Part B only: BCVA of \<75 and \>10 ETDRS letters (Snellen equivalent of worse than 20/32 and better than 20/630) at the screening visit and on day 1

Exclusion (4)

- BCVA of d30 ETDRS letters (Snellen equivalent of 20/250 or worse) at the screening visit and/or on day 1
- Intraocular Pressure (IOP) \<5 mm Hg at the screening visit and/or on day 1
- IOP \>25 mm Hg on day 1. Participants are permitted to take IOP-lowering eye drops
- Confirmed or suspected infectious uveitis, as defined in the protocol

Locations (4 total)

Illinois Retina Associates, Oak Park, Illinois, United States
Tennessee Retina, Nashville, Tennessee, United States
Retina Consultants of Texas - Houston, Bellaire, Texas, United States
... and 1 more locations